Build a Real-Time AI Fetal Cardiac Screening Platform

1. 1

   Center the product on guiding the live scan

   The strategic insight is that ultrasound AI's highest value is real-time guidance during acquisition, not post-scan reading, because ultrasound is operator-dependent. Your platform tracks anatomy, verifies exam completeness, and flags structural markers while the sonographer scans. Building for the live moment, not the saved image, is what makes this different from radiology AI.

2. 2

   Assemble fetal-imaging plus ML expertise and data

   Detecting congenital heart defects in real time requires deep fetal-cardiology domain knowledge, machine-learning capability, and large volumes of labeled ultrasound exams; the cited benchmark was built on more than 90,000 exams reaching over 96 percent accuracy. Data access and clinical expertise are the core assets. Secure both before promising accuracy.

3. 3

   Validate clinically and pursue FDA clearance

   Clinical validation and regulatory clearance are the gate: you must prove accuracy in real clinical settings and clear the FDA before broad sale. This is why the venture is Series A-scale (an 11 million euro round is cited in the field). Plan validation and regulatory strategy as central, funded workstreams, not afterthoughts.

4. 4

   Go to market through OEM app-stores

   Rather than build a hospital sales force from scratch, the efficient channel is a manufacturer's ultrasound app-store (such as GE HealthCare's Voluson Solution Store), which sells your cleared AI onto an installed base of scanners. This app-store distribution is a documented go-to-market shortcut (its own card). Design integration for the OEM platforms your buyers already own.

5. 5

   Price as per-site or enterprise software

   Revenue is software licensing via the OEM app-store, priced per-site or as enterprise agreements with hospitals and OB practices. The recurring software model, layered on the OEM's hardware, is the business. Structure pricing to fit how hospitals buy through those platforms.

6. 6

   Plan for competing against the OEM's own AI

   A named risk is that the hardware manufacturer hosting your app also builds competing in-house AI tools, so you must stay ahead on accuracy, specialty focus, and clinical evidence. Differentiation and continued validation are ongoing necessities. Know that the platform that distributes you may also compete with you.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Clinical-AI founders with fetal-imaging expertise and access to validation capital

Not for: Teams without clinical-validation capital, anyone who would claim beyond validated scope, and those who build post-scan readers instead of live guidance.